Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 20:63:211-229.
doi: 10.1146/annurev-pharmtox-051921-092701. Epub 2022 Jan 8.

Pharmacogenetics of Antiplatelet Therapy

Matteo Castrichini  1 , Jasmine A Luzum  2 , Naveen Pereira  1
Affiliations
Review

Pharmacogenetics of Antiplatelet Therapy

Matteo Castrichini et al. Annu Rev Pharmacol Toxicol. .

Abstract

Antiplatelet therapy is used in the treatment of patients with acute coronary syndromes, stroke, and those undergoing percutaneous coronary intervention. Clopidogrel is the most widely used antiplatelet P2Y12 inhibitor in clinical practice. Genetic variation in CYP2C19 may influence its enzymatic activity, resulting in individuals who are carriers of loss-of-function CYP2C19 alleles and thus have reduced active clopidogrel metabolites, high on-treatment platelet reactivity, and increased ischemic risk. Prospective studies have examined the utility of CYP2C19 genetic testing to guide antiplatelet therapy, and more recently published meta-analyses suggest that pharmacogenetics represents a key treatment strategy to individualize antiplatelet therapy. Rapid genetic tests, including bedside genotyping platforms that are validated and have high reproducibility, are available to guide selection of P2Y12 inhibitors in clinical practice. The aim of this review is to provide an overview of the background and rationale for the role of a guided antiplatelet approach to enhance patient care.

Keywords: CYP2C19; dual antiplatelet therapy; guided antiplatelet therapy; pharmacogenetics; pharmacogenomics; precision medicine.

PubMed Disclaimer

Figures

Figure 1
Figure 1
A proposed algorithm using CYP2C19 pharmacogenetic testing to individualize oral P2Y12 inhibitor therapy in patients with coronary artery disease on the basis of the meta-analysis results. The overall prevalence of 30% CYP2C19 LOF carriers does not reflect the prevalence of up to 50% observed in Asian populations. Abbreviations: ACS, acute coronary syndrome; CAD, coronary artery disease; CI, confidence interval; LOF, loss-of-function; PCI, percutaneous coronary intervention; RCT, randomized clinical trial. Figure adapted from Reference 110. Illustrations copyright Mayo Clinic.
See this image and copyright information in PMC

References

    1. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, et al. 2009. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11):1045–57 - PubMed
    1. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, et al. 2007. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20):2001–15 - PubMed
    1. Karve AM, Seth M, Sharma M, LaLonde T, Dixon S, et al. 2015. Contemporary use of ticagrelor in interventional practice (from Blue Cross Blue Shield of Michigan Cardiovascular Consortium). Am. J. Cardiol. 115(11):1502–6 - PubMed
    1. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, et al. 2016. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation 134(10):e123–55. Erratum. 2016. Circulation 134(10):e192–94 - PubMed
    1. Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. 2003. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107(23):2908–13 - PubMed